The possible advantage of extending dAPT with respect to ischemic consequences must be weighed against the increased risk of predominantly extracranial hemorrhagic complications [88].Post-CEA or CAS, antiplatelet therapies have shown an increased risk of stroke with <180 days of prescribed post-CAS P2Y12-inhibition (HR = 1.421, 95% CI: 1.038-1.946; 90-179 prescribed days: HR = 1.484, 95% CI: 1.045-2.106). This evidence concerns the gene P2RY12 and Stroke.